Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

NCT04450836 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

234

Enrollment

OTHER

Sponsor class

Stopped Following the presentation of the SUNLIGHT study results at ASCO GI and the rapid change in patient management in the majority of centers, the IDMC experts recommended halting inclusion in the SOREGATT study with immediate effect.

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Regorafenib then Trifluridine/Tipiracil
DRUG: Trifluridine/Tipiracil then Regorafenib

Sponsor

UNICANCER